跳至主要内容
临床试验/NL-OMON51011
NL-OMON51011招募中不适用

The influence of pancreatic function on the pharmacokinetics of ivacaftor in patients with cystic fibrosis - IPAI

HagaZiekenhuis0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Signed informed consent form (ICF )
  • - 18 years or older on the date of signed informed consent
  • - Diagnosis of cystic fibrosis confirmed by genotype analysis
  • - Current use of tezacaftor/ivacaftor in combination with ivacaftor
  • - If pancreas insufficient, current use of amylase/lipase/protease, creon

排除标准

  • - Use of drugs that have a known influence on the CYP3A enzyme (inducers or
  • inhibitors)
  • - Pulmonary exacerbation with hospital admission in the month before study
  • participation (defined as need for intravenous antibiotics)
  • - Pregnancy or breast feeding

研究者

相似试验